Pharmaceutical Executive-02-01-2016

February 18, 2016

18 February, 2016.

February 09, 2016

In the patent scrum, a litigator finds her true self.

February 08, 2016

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.

February 05, 2016

Canada’s Rx&D, the industry’s oldest functioning trade association, recently changed its name-with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market.

February 05, 2016

A closer reading of this year's JP Morgan investor conference identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.

February 05, 2016

An advocate of business system automation in the global pharma supply chain offers a six-pronged approach to adapting to the realities of a new age of mounting regulation and customer expectations.

February 01, 2016

More oversight of regulatory programs and policies planned by GOP critics.

February 01, 2016

Defending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.

February 01, 2016

What the drug industry stands to gain - or lose - from the unthinkable: Britain departing the European Union.

February 01, 2016

Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.

February 01, 2016

In tandem with South Africa’s institutional advancements, driven by sweeping social and macroeconomic reforms, the pharma industry in the region is capitalizing on its core fundamentals: rising consumer disposable income, a positive demographic profile linked to an aging population, and a diverse disease burden requiring novel cures and treatments.

February 01, 2016

Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.